Thyrocare TechnologiesQ4 FY23

Thyrocare Technologies Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹506.95P/E: 46.1Market Cap: ₹8.1K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

No

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2
- Growth is expected to stabilize going forward; the high growth rates of the past are not anticipated to continue next year. - Two more non-operational centers (out of a base of 10) are expected to become operational in the second half of the year, potentially adding ~10% volume impact. - Pricing is largely stabilized with limited scope for further price increases in the current market. - The business is seen as more organic and annuity in nature, with anticipated pure scan volume growth around 10-12% annually. - Non-COVID volume growth has been strong (39% YoY), but this high growth rate is also expected to moderate. - International expansion is in early stages with Rs. 20 crores CAPEX allocated across 3 geographies; this is not expected to materially impact revenue in the short term. - Radiology business shows strong recovery and growth (47% YoY). Overall, expect moderate organic volume growth with stable pricing and gradual expansion.

See what Thyrocare Technologies management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • No indication of any immediate or planned fundraising through equity or debt was mentioned.
  • The company is currently generating healthy operating cash flow (Rs. 129 crores last year).
  • It prefers using debt financing for equipment purchases rather than shareholder cash.
  • Cash deployment is conservative, focusing on prudent capital allocation without large CAPEX or acquisitions.
  • International expansion is planned with a modest initial CAPEX allocation of Rs. 20 crores across three geographies.
  • No mention of equity dilution or fresh share issuance; existing ESOPs are non-cash and non-dilutive in the short term.
  • Management emphasizes returning cash to shareholders via dividends rather than retaining cash for aggressive growth or fundraising.

See what Thyrocare Technologies management said on order book — free account, 30 seconds.

Capex plans

Yes
  • FY23 CAPEX was Rs. 41 crores, mainly spent on setting up 6 regional labs (Rs. 5-6 crores each) and 2 new nuclear centers.
  • FY24 CAPEX forecast is around Rs. 40 crores, including Indian operations (Goa lab and a couple of satellite labs) and some nuclear lab shifts.
  • Rs. 20 crores allocated for international expansion in FY24, primarily for Africa, Middle East, and Southeast Asia markets, expected to be spent mostly in Q3 and Q4.
  • International expansion CAPEX is modest (~Rs. 6-7 crores per geography), still at MoU stage; minimal material impact expected on EBITDA or balance sheet in near term.
  • No plans for large acquisitions; company prefers debt financing for equipment to preserve shareholder cash.
  • Dividend policy remains aggressive unless a lucrative growth opportunity arises.

Track Thyrocare Technologies — get its next earnings analysis in your feed

How does Thyrocare Technologies rank vs peers in Healthcare Services?

Pro feature
ThisThyrocare Technologies
Rev 2Mar 3

How does Thyrocare Technologies rank in Healthcare Services?

Compare Thyrocare Technologies against every Healthcare Services company (Q4 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →